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Abstract
Background: The data from individual observational studies included in meta-analyses of drug effects are collected
either from ad hoc methods (i.e. “primary data”) or databases that were established for non-research purposes (i.e.
“secondary data”). The use of secondary sources may be prone to measurement bias and confounding due to over-
the-counter and out-of-pocket drug consumption, or non-adherence to treatment. In fact, it has been noted that
failing to consider the origin of the data as a potential cause of heterogeneity may change the conclusions of a
meta-analysis. We aimed to assess to what extent the origin of data is explored as a source of heterogeneity in
meta-analyses of observational studies.
Methods: We searched for meta-analyses of drugs effects published between 2012 and 2018 in general and
internal medicine journals with an impact factor > 15. We evaluated, when reported, the type of data source
(primary vs secondary) used in the individual observational studies included in each meta-analysis, and the
exposure- and outcome-related variables included in sensitivity, subgroup or meta-regression analyses.
Results: We found 217 articles, 23 of which fulfilled our eligibility criteria. Eight meta-analyses (8/23, 34.8%) reported
the source of data. Three meta-analyses (3/23, 13.0%) included the method of outcome assessment as a variable in
the analysis of heterogeneity, and only one compared and discussed the results considering the different sources of
data (primary vs secondary).
Conclusions: In meta-analyses of drug effects published in seven high impact general medicine journals, the origin
of the data, either primary or secondary, is underexplored as a source of heterogeneity.
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Background
Specific research questions are ideally answered through
tailor-made studies. Although these ad hoc studies
provide more accurate and updated data, designing a
completely new project may not represent a feasible
strategy [1, 2]. On the other hand, clinical and administra-
tive databases used for billing and other fiscal purposes
(i.e. “secondary data”) are a valuable resource as an alter-
native to ad hoc methods (i.e. “primary data”) since it is
easier and less costly to reuse the information than col-
lecting it anew [3]. The potential of secondary automated
databases for observational epidemiological studies is
widely acknowledged; however, their use is not without
challenges, and many quality requirements and methodo-
logical pitfalls must be considered [4].
Meta-analysis represents one of the most valuable
tools for assessing drug effects as it may lead to the best
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evidence possible in epidemiology [5]. Consequently, its
use for making relevant clinical and regulatory decisions
on the safety and efficacy of drugs is dramatically
increasing [6]. Existence of heterogeneity in a given
meta-analysis is a feature that needs to be carefully
described by analyzing the possible factors responsible
for generating it [7]. In this regard, the results of a re-
cent study [8] show that whether the origin of the data
(primary vs secondary) is explored as a potential cause
of heterogeneity may change the conclusions of a
meta-analysis due to an effect modification [9]. Thus,
considering the source of data as a variable in sensitivity
and subgroup analyses, or meta-regression analyses,
seems crucial to avoid misleading conclusions in
meta-analyses of drug effects.
Given the evidence noted [8, 9], we surveyed published
meta-analyses in a selection of high-impact journals over
a 6-year period, to assess to what extent the origin of
the data, either primary or secondary, is explored as a
source of heterogeneity in meta-analyses of observa-
tional studies.
Methods
Meta-analysis selection and data collection process
General and internal medicine journals with an impact
factor > 15 according to the Web of Science were included
in the survey [10]. This method has been widely used to
assess quality as well as publication trends in medical
journals [11–13]. The rationale is that meta-analyses
published in high impact journals: (1) are likely to be
rigorously performed and reported due to the exhaustive
editorial process [12, 14]; and, (2) in general, exert a
higher influence on medical practice due to the major role
played by these journals in the dissemination of the new
medical evidence [14, 15]. We searched MEDLINE on
May 2018 using the search terms “meta-analysis” as publi-
cation type and “drug” in any field between January 1,
2012 and May 7, 2018 in the New England Journal of
Medicine (NEJM), Lancet, Journal of the American Med-
ical Association (JAMA), British Medical Journal (BMJ),
JAMA Internal Medicine (JAMA Intern Med), Annals of
Internal Medicine (Ann Intern Med), and Nature Reviews
Disease Primers (Nat Rev Dis Primers).
Two investigators (GP-R, FR) independently assessed
publications for eligibility. Abstracts were screened and if
deemed potentially relevant, full text articles were re-
trieved. Articles were excluded if they met any of the fol-
lowing conditions: (1) were not a meta-analysis of
published studies, (2) no drug effects were evaluated, (3)
only randomized clinical trials were included in the
meta-analysis (in order to consider observational studies),
(4) less than two observational studies were included in
the meta-analysis (since with a single study it would not
have been possible to calculate a pooled measure). When
a meta-analysis included both observational studies and
clinical trials, only observational studies were considered.
A data extraction form was developed previously to ex-
tract information from articles. Two investigators (GP-R,
FR) independently extracted and recorded the information
and resolved discrepancies by referring to the original re-
port. If necessary, a third author (AF) was asked to resolve
disagreements between the investigators.
When available we extracted the following data from
each eligible meta-analysis: first author, publication year,
journal, drug(s) exposure and outcome(s); number of in-
dividual studies included in the meta-analysis based on
each type of data source used (primary vs secondary),
for both exposure and outcome assessment; and
exposure- and outcome-related variables included in
sensitivity, subgroup or meta-regression analyses. We
extracted data directly from the tables, figures, text, and
supplementary material of the meta-analyses, not from
the individual studies.
Assessment of exposure and outcome
We considered “primary data” the information on drug
exposure collected directly by the researchers using inter-
views –personal or by telephone– or self-administered
questionnaires. The origin of the data was also considered
primary when objective diagnostic methods were used for
the determination of drug exposure (e.g. blood test).
“Secondary data” are data that were formerly collected for
other purposes than that of the study at hand and that
were included in databases on drug prescription (e.g. pre-
scription registers, medical records/charts) and dispensing
(e.g. computerized pharmacy records, insurance claims
databases). Regarding the outcome assessment, we consi-
dered primary data when an objective confirmation is
available that endorses them (e.g. confirmed by individual
medical ad hoc diagnosis, lab test or imaging results).
These criteria are based on those commonly used in the
risk assessment of bias for observational studies [16–19].
Results
MEDLINE search results yielded 217 articles from the
major general medical journals (3 from NEJM, 46 from
Lancet, 26 from JAMA, 85 from BMJ, 19 from JAMA
Intern Med, 38 from Ann Intern Med, and 0 from Nat
Rev Dis Primers) (see Fig. 1). A total of 194 articles were
excluded (see list of excluded articles with reasons for
exclusion in Additional file 1) leaving 23 articles to be
examined [20–42]. General characteristics of the 23 in-
cluded meta-analyses are outlined in Table 1.
Source of exposure and outcome data
Table 2 summarizes the evidence regarding the type of data
source included in each meta-analysis, according to the in-
formation presented in the data extraction tables of the
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article. The information was evaluated taking the study de-
sign into account. Only eight meta-analyses [21, 24, 26, 31,
32, 34, 38, 41] reported the source of data, three of them
[31, 34, 38] reporting mixed sources for both the exposure
and outcome assessment. Five meta-analyses [21, 24, 26,
32, 41] reported only secondary sources for the exposure
assessment, three of them [21, 24, 41] reporting as well only
secondary sources for the outcome assessment, while in the
other two [26, 32] only primary and mixed sources for the
outcome assessment were reported respectively.
Source of data in the analysis of heterogeneity
All but two [20, 42] of the meta-analyses performed sub-
group and/or sensitivity analyses. Although three of
them [23, 34, 36] considered the methods of outcome
assessment – type of diagnostic assay used for Clostrid-
ium difficile infection, method of venous thrombosis
diagnosis confirmation, and type of scale for psychosis
symptoms assessment respectively– as stratification vari-
ables, only the second referred to the origin of the data.
Only five meta-analyses [22, 28, 33, 35, 39] included
meta-regression analyses to describe heterogeneity, none
of which considered the source of data as an explanatory
variable. Other findings for the inclusion of the data
source as a variable in the analysis of heterogeneity are
presented in Table 3.
We finally assessed if the influence of the data origin
on the conclusions of the meta-analyses was discussed
by their respective authors. We found that only four
meta-analyses [21, 31, 32, 34] noted limitations derived
from the type of data source used.
Discussion
The findings of this research suggest that the origin of the
data, either primary or secondary, is underexplored as a
source of heterogeneity and an effect modifier in meta-ana-
lyses of drug effects published in general medicine journals
with high impact. Few meta-analyses reported the source of
data and only one [34] of the articles included in our survey
compared and discussed the meta-analysis results consider-
ing the different sources of data.
Although it is usual to consider the design of the indi-
vidual studies (i.e. case-control, cohort or experimental
studies) in the analysis of the heterogeneity of a
meta-analysis [43, 44], the type of data source (primary vs
secondary) is still rarely used for this purpose [9, 45]. In
fact, the current reporting guidelines for meta-analyses,
such as MOOSE (Meta-analysis Of Observational Studies
in Epidemiology) [18] or PRISMA (Preferred Reporting
Items for Systematic reviews and Meta-Analyses) [46, 47],
do not recommend that authors specifically report the
origin of the data. This is probably due to the close























Records excluded based on title and 
abstracts: n=173
1. Not a meta-analysis of published 
studies (4)
2. No drug effects evaluated (32)
3. Only clinical trials included (137)
Full-text articles assessed 
for eligibility:
n=44
Full-text articles excluded: n=21
1. Not a meta-analysis of published 
studies (5)
2. No drug effects evaluated (6)
3. Only clinical trials included (8)




Fig. 1 Flow diagram of literature search results
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relationship that exists between the study design and the
type of data source used, despite the fact that each criter-
ion has its own basis. Performing this additional analysis
is a simple task that involves no additional cost. Failure to
do so may lead to diverging conclusions [8].
Conclusions about the effects of a drug that are
derived from studies based exclusively on data from
secondary sources may be dicey, among other reasons,
because no information is collected on consumption of
over-the-counter drugs (i.e. drugs that individuals can buy
without a prescription) [48] and/or out-of-pocket expenses
for prescription drugs (i.e. costs that individuals pay out of
their own cash reserves) [49]. In the health care and insu-
rance context, out-of-pocket expenses usually refer to de-
ductibles, co-payments or co-insurance. Figure 2 shows
the model that we propose to describe the relationship
between the different data records according to their ori-
gin, including the possible loss of information (susceptible
to be registered only through primary research).
Failure to take these situations into account may lead to
exposure measurement bias [48, 49]. Consumption of a
drug may be underestimated when only prescription data
Table 2 Reporting of the data source in the data extraction tables of the included meta-analyses

















1ry 2ry NR 1ry 2ry NR 1ry 2ry NR 1ry 2ry NR
Weiss J [20]
Harms outcomes
No . . . . . . No . . . . . .
Bally M [21] Yes 0 3b 0 0 1 0 Yes 0 3b 0 0 1 0
Sordo L [22] Noa . . . . . . Noa . . . . . .
Tariq R [23] Noac . . . . . . Noa . . . . . .
Maruthur NM [24] Yesd 0 3 0 . . . Yesd 0 3 0 . . .
Paul S [25] Noa . . . . . . Noa . . . . . .
Li L [26]
Heart failure
Yes 0 1 2 0 0 1 Yes 1 0 2 0 0 1
Li L [26]
Hospital admissions for heart failure
Yes 0 0 6 0 0 2 Yes 3 0 3 0 0 2
Molnar AO [27] Noa . . . . . . Noa . . . . . .
Ziff OJ [28] Noa . . . . . . Noa . . . . . .
CGESOC [29] No . . . . . . No . . . . . .
Bellemain-Appaix A [30] Noa . . . . . . Noa . . . . . .
Grigoriadis S [31] Yes 2 3 0 1 1 0 Yes 4 1 0 2 0 0
Li L [32] Yes 0 1 2 0 1 1 Yes 1 2 0 0 0 2
Kalil AC [33] No . . . . . . No . . . . . .
Stegeman BH [34] Yes 0 9 0 8 8 1 Yes 4 5 0 5 12 0
Maneiro JR [35] Noa . . . . . . Noa . . . . . .
Hartling L [36] No . . . . . . No . . . . . .
Hsu J [37] Noa . . . . . . Noa . . . . . .
Caldeira D [38] Yes 2 2 7 0 7 1 Yes 0 1 10 3 1 4
MacArthur GJ [39] Noa . . . . . . Noa . . . . . .
Mantha S [40] No . . . . . . No . . . . . .
Silvain J [41] Yes 0 7 0 . . . Yes 0 7 0 . . .
McKnight RF [42] No . . . . . . No . . . . . .
Abbreviations: 1ry number of individual studies in each MA based on primary data sources, 2ry number of individual studies in each MA based on secondary data
sources, NR number of individual studies in each MA with not reported data source
aAlthough the meta-analysis shows the results of methodological quality assessment based on a standardized scale, it does not indicate the type of data source
used for each individual observational study included in the meta-analysis
bCohort with nested case-control analysis
cThe meta-analysis reports that most of the included observational studies assessed medication exposure through a review of medical records
dThe meta-analysis reports only data from high-quality observational studies
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is used as secondary source without additionally consider-
ing unregistered consumption, such as over-the-counter
consumption (e.g. oral contraceptives [34, 50]), that may
only be available from a primary database. Alternatively,
this may occur when dispensing data for billing purposes
(reimbursement) are used for clinical research, if
out-of-pocket expenses are not considered (see Fig. 2).
The portion of the medical bill that the insurance
company does not cover, and that the individual must pay
on his own, is unlikely to be recorded. Data on the sale of
over-the-counter drugs will also not be available in this
scenario.
The reverse situation may also occur and consumption
may be overestimated when only prescription data is used,
if the prescribed drug is not dispensed by the pharmacist;
or when dispensing data is used, if the drug is not really
consumed by the patient. While primary non-adherence
occurs when the patient does not pick up the medication
after the first prescription, secondary non-adherence re-
fers to the absence of dispensing of successive prescrip-
tions among patients with primary adherence, or to
inadequate secondary adherence (i.e. ≥20% of time with-
out adequate medication) [51] (see Fig. 2). In some dis-
eases the medication adherence is very low [52–55], with
percentages of primary non-adherence (never dispensed)
that exceed 30% [56]. It should be noted that the impact
of non-adherence varies from medication to medication.
Therefore, it must be defined and measured in the context
of a particular therapy [57].
Moreover, failing to take into consideration the por-
tion of consumption due to over-the-counter and/or
out-of-pocket expenses may lead to confounding, as that
variable may be related to the socio-economic level and/
or to the potential of access to the health system [58],
which are independent risk factors of adverse outcomes
of some medications (e.g. myocardial infarction [21, 28,
30, 41]). Given the presence of high-deductible health
plans and the high co-insurance rate for some drugs,
cost-sharing may deter clinically vulnerable patients
from initiating essential medications, thus negatively
affecting patient adherence [59, 60].
Outcome misclassification may also give rise to meas-
urement bias and heterogeneity [61]. This occurs, for ex-
ample, in the meta-analysis that evaluates the
relationship between combined oral contraceptives and
the risk of venous thrombosis [34]. In the studies with-
out objective confirmation of the outcome, the women
were classified erroneously regardless of the use of con-
traceptives. This led to a non-differential misclassifica-
tion that may have underestimated the drug–outcome
relationship, especially when the third generation of pro-
gestogen is analysed: Risk ratio (RR) primary data = 6.2
(95% confidence interval (CI) 5.2–7.4), RR secondary
data = 3.0 (95% CI 1.7–5.4) [34].
On the one hand, medical records are often considered
as being the best information source for outcome vari-
ables. However, they present important limitations in the
recording of medications taken by patients [62]. On the
other hand, dispensing records show more detailed data
on the measurement of drug exposure. However, they do
not record the over-the-counter or out-of-pocket drug
consumption at an individual level [48, 49], apart from
offering unreliable data on outcome variables [62, 63].
Limitations
The first limitation of this research is that its findings
may not be applicable to journals not included in our
















Fig. 2 Conceptual model of individual data recording. * Never dispensed. † Absence of dispensing of successive prescriptions (or self-medication)
among patients with primary adherence, or inadequate secondary adherence
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Despite the widespread use of the impact factor
metric [64], this method has inherent weaknesses [65,
66]. However, meta-analyses published in high impact
general medicine journals are likely to be most rigor-
ously performed and reported due to their greater
availability of resources and procedures [12, 14]. It is
then expected that the overall reporting quality of ar-
ticles published in other lesser-known journals will be
similar. Another limitation would be related to the
limited search period. In this sense, and given that
the general tendency is the improvement of the
methodology of published meta-analyses [67, 68], we
find no reason to suspect that the adverse conclu-
sions could be different before the period from 2012
to 2018. Although it exceeds the objective of this re-
search, one last limitation may be the inability to reanalyse
the included meta-analyses stratifying by the type of data
source since our study design restricts the conclusions to
the published data of the meta-analyses, which were insuf-
ficiently reported, or the number of individual studies in
each stratum was insufficient to calculate a pooled meas-
ure (see Table 2).
Conclusions
Owing to automated capture of data on drug prescrip-
tion and dispensing that are used for billing and other
administration purposes, as well as to the implementa-
tion of electronic medical records, secondary databases
have generated enormous possibilities. However, neither
their limitations, nor the risk of bias that they pose
should be overlooked [69]. Thus, researchers should
consider the link between administrative databases and
medical records, as well as the advisability of combining
secondary and primary data in order to minimize the oc-
currence of biases due to the use of any of these
databases.
No source of heterogeneity in a meta-analysis should
ever be considered alone but always as part of an inter-
connected set of potential questions to be addressed. In
particular, the origin of the data, either primary or sec-
ondary, is insufficiently explored as a source of hetero-
geneity in meta-analyses of drug effects, even in those
published in high impact general medicine journals.
Thus, we believe that authors should systematically
include the source of data as an additional variable in
subgroup and sensitivity analyses, or meta-regression
analyses, and discuss its influence on the meta-analysis
results. Likewise, reviewers, editors and future gui-
delines should also consider the origin of the data as a
potential cause of heterogeneity in meta-analyses of
observational studies that include both primary and
secondary data. Failure to do this may lead to mislead-
ing conclusions, with negative effects on clinical and
regulatory decisions.
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